adenoid cystic carcinoma of the salivary glands
Conditions
Brief summary
Objective response rate
Detailed description
Progression-free survival, Overall survival, Duration of response, Disease specific survival, Quality of life assessment (according to the EORTC QLQ-C30 and EORTC QLQ-H&N43 questionnaires) and the numeric rating scale (NRS), The number and percentage of patients who experienced adverse events of various severity grades according to CTCAE, laboratory test results and vital signs, Quantitative assessment of ¹⁷⁷Lu-PSMA radiotracer uptake on post-therapy scintigraphy after the first and third treatment cycles
Interventions
DRUGPluvicto 1 000 MBq/mL solution for injection/infusion
Sponsors
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival, Overall survival, Duration of response, Disease specific survival, Quality of life assessment (according to the EORTC QLQ-C30 and EORTC QLQ-H&N43 questionnaires) and the numeric rating scale (NRS), The number and percentage of patients who experienced adverse events of various severity grades according to CTCAE, laboratory test results and vital signs, Quantitative assessment of ¹⁷⁷Lu-PSMA radiotracer uptake on post-therapy scintigraphy after the first and third treatment cycles | — |
Outcome results
None listed